HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

J Donald Easton Selected Research

Embolic Stroke

1/2022Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial.
11/2021Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial.
1/2021Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis.
1/2021Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
9/2020Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation.
1/2020Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups.
1/2019Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
1/2017Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.
7/2016Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
12/2015Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS).
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


J Donald Easton Research Topics

Disease

51Stroke (Strokes)
03/2022 - 11/2002
30Ischemic Stroke
03/2022 - 01/2003
26Transient Ischemic Attack
03/2022 - 09/2004
24Hemorrhage
01/2021 - 11/2008
12Embolic Stroke
01/2022 - 08/2011
12Atrial Fibrillation
09/2020 - 06/2006
10Myocardial Infarction
01/2018 - 01/2003
8Vascular Diseases (Vascular Disease)
01/2018 - 06/2004
5Embolism (Embolus)
09/2020 - 03/2010
4Brain Ischemia (Cerebral Ischemia)
01/2018 - 03/2002
4Peripheral Arterial Disease
02/2011 - 09/2005
3Intracranial Hemorrhages (Intracranial Hemorrhage)
01/2019 - 07/2016
3Thrombosis (Thrombus)
04/2014 - 09/2005
2Infarction (Infarctions)
03/2022 - 06/2009
2Carotid Stenosis (Carotid Artery Stenosis)
01/2021 - 01/2019
2Ischemia
01/2020 - 06/2009
2Cerebral Hemorrhage
10/2018 - 10/2003
2Hemorrhagic Stroke
09/2017 - 09/2011
2Pathologic Constriction (Stenosis)
04/2017 - 01/2017
2Atherosclerosis
01/2017 - 01/2003
2Peripheral Vascular Diseases (Peripheral Vascular Disease)
06/2009 - 03/2008
2Intracranial Sinus Thrombosis (Sinus Thrombosis)
06/2008 - 09/2004
1Patent Foramen Ovale
01/2021
1Brain Infarction
09/2017
1Atrial Flutter (Flutter, Atrial)
06/2012
1Lacunar Stroke
08/2011
1Weight Loss (Weight Reduction)
08/2010
1Obesity
08/2010
1Hypercholesterolemia
10/2008
1Hypertension (High Blood Pressure)
03/2008
1Heart Failure
03/2008
1Chronic Kidney Failure (Chronic Renal Failure)
03/2008
1Acute Coronary Syndrome
05/2007
1Coronary Disease (Coronary Heart Disease)
06/2006
1Cardiovascular Diseases (Cardiovascular Disease)
04/2006
1Cerebrovascular Disorders (Cerebrovascular Occlusion)
01/2003
1Unstable Angina
01/2003

Drug/Important Bio-Agent (IBA)

48Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
03/2022 - 11/2002
23Clopidogrel (Plavix)FDA Link
03/2022 - 11/2002
11TicagrelorIBA
12/2020 - 12/2015
9DabigatranFDA Link
01/2022 - 03/2012
9apixabanIBA
09/2020 - 03/2010
8Warfarin (Coumadin)FDA LinkGeneric
09/2020 - 03/2010
7AnticoagulantsIBA
01/2021 - 09/2004
7Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA
01/2019 - 01/2003
6ThrombinFDA Link
01/2022 - 12/2015
4Vitamin KFDA Link
09/2020 - 03/2010
3Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2019 - 06/2006
3Factor Xa InhibitorsIBA
04/2014 - 03/2010
3Heparin (Liquaemin)FDA LinkGeneric
06/2008 - 03/2002
3Tissue Plasminogen Activator (Alteplase)FDA Link
06/2008 - 10/2003
3Dipyridamole (Persantine)FDA LinkGeneric
06/2008 - 09/2004
3Glycoproteins (Glycoprotein)IBA
03/2008 - 06/2006
22'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA
01/2021 - 01/2020
2Pharmaceutical PreparationsIBA
01/2017 - 08/2010
2tetrachloroisophthalonitrile (Bravo)IBA
11/2008 - 06/2006
2Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA
06/2008 - 09/2004
2Purinergic P2Y Receptor AntagonistsIBA
09/2005 - 01/2003
1CreatinineIBA
01/2022
1N(4)-oleylcytosine arabinosideIBA
09/2020
1Cytochrome P-450 CYP2C19IBA
01/2020
1Cilostazol (Pletal)FDA LinkGeneric
01/2019
1RivaroxabanIBA
01/2019
1Phenprocoumon (Liquamar)FDA Link
10/2018
1Blood Glucose (Blood Sugar)IBA
08/2010
1EndocannabinoidsIBA
08/2010
1Triglycerides (Triacylglycerol)IBA
08/2010
1HDL CholesterolIBA
08/2010
1RimonabantIBA
08/2010
1cyclo(Arg-Pro) (CI 4)IBA
08/2010
1Retinaldehyde (Retinal)IBA
06/2009
1Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
10/2008
1Hypoglycemic Agents (Hypoglycemics)IBA
10/2008
1ThromboxanesIBA
10/2008
12,5-dichloro-4-bromophenol (B 2)IBA
10/2008
1sibrafibanIBA
06/2006
1Glucose (Dextrose)FDA LinkGeneric
10/2003
1antineoplaston A10 (A 10)IBA
01/2003

Therapy/Procedure

27Therapeutics
12/2021 - 01/2003
4Secondary Prevention
12/2019 - 04/2014
2Contraindications
10/2012 - 03/2012
2Thrombolytic Therapy
06/2008 - 09/2004
1Anesthesia
06/2009
1Percutaneous Coronary Intervention
03/2008